OBJECTIVE: To compare the effects of an angiotensin receptor blocker(ARB)-based regimen versus a non-ARB based regimen on diastolic function and neurohormones in patients with hypertension and diastolic dysfunction. METHODS:97 patients with a systolic blood pressure (SBP) > or =140 mmHg, a left ventricular ejection fraction >0.50, and echocardiographic evidence of diastolic dysfunction were randomly assignment to open-label treatment with eprosartan (with other anti-hypertensives; n = 47) or other anti-hypertensives alone (n = 50). Echocardiography, including tissue Doppler imaging (TDI), and neurohormones were done at baseline and after 6 months. RESULTS:Mean age was 65 (+/-10) years and 64% was female. During 6 months of treatment, SBP decreased from 157 +/- 16 to 145 +/- 18 mmHg in the eprosartan group and from 158 +/- 17 to 141 +/- 18 mmHg in the control group (both p < 0.001; p = ns between groups). Diastolic function was unaffected in both groups and there was no correlation between changes in SBP and changes in mean TDI (r = -0.06; p = 0.58). Aldosterone levels decreased in the eprosartan group, but other neurohormones remained largely unchanged. Change in SBP was however related to the change in NT-proBNP (r = 0.26; p = 0.019). CONCLUSION:Lowering blood pressure, either with eprosartan or other anti-hypertensives in hypertensive patients with diastolic dysfunction did not change diastolic function after 6 months of treatment, but was associated with a decrease of NT-proBNP.
RCT Entities:
OBJECTIVE: To compare the effects of an angiotensin receptor blocker(ARB)-based regimen versus a non-ARB based regimen on diastolic function and neurohormones in patients with hypertension and diastolic dysfunction. METHODS: 97 patients with a systolic blood pressure (SBP) > or =140 mmHg, a left ventricular ejection fraction >0.50, and echocardiographic evidence of diastolic dysfunction were randomly assignment to open-label treatment with eprosartan (with other anti-hypertensives; n = 47) or other anti-hypertensives alone (n = 50). Echocardiography, including tissue Doppler imaging (TDI), and neurohormones were done at baseline and after 6 months. RESULTS: Mean age was 65 (+/-10) years and 64% was female. During 6 months of treatment, SBP decreased from 157 +/- 16 to 145 +/- 18 mmHg in the eprosartan group and from 158 +/- 17 to 141 +/- 18 mmHg in the control group (both p < 0.001; p = ns between groups). Diastolic function was unaffected in both groups and there was no correlation between changes in SBP and changes in mean TDI (r = -0.06; p = 0.58). Aldosterone levels decreased in the eprosartan group, but other neurohormones remained largely unchanged. Change in SBP was however related to the change in NT-proBNP (r = 0.26; p = 0.019). CONCLUSION: Lowering blood pressure, either with eprosartan or other anti-hypertensives in hypertensivepatients with diastolic dysfunction did not change diastolic function after 6 months of treatment, but was associated with a decrease of NT-proBNP.
Authors: Arnfried U Klingbeil; Markus Schneider; Peter Martus; Franz H Messerli; Roland E Schmieder Journal: Am J Med Date: 2003-07 Impact factor: 4.965
Authors: Kristian Wachtell; Jonathan N Bella; Jens Rokkedal; Vittorio Palmieri; Vasilios Papademetriou; Björn Dahlöf; Tapio Aalto; Eva Gerdts; Richard B Devereux Journal: Circulation Date: 2002-03-05 Impact factor: 29.690
Authors: Jasper W L Hartog; Adriaan A Voors; Casper G Schalkwijk; Jean Scheijen; Tom D J Smilde; Kevin Damman; Stephan J L Bakker; Andries J Smit; Dirk J van Veldhuisen Journal: Eur Heart J Date: 2007-11-05 Impact factor: 29.983
Authors: G W K Yip; M Wang; T Wang; S Chan; J W H Fung; L Yeung; T Yip; S-T Lau; C-P Lau; M-O Tang; C-M Yu; J E Sanderson Journal: Heart Date: 2008-01-20 Impact factor: 5.994
Authors: Michele M Ciulla; Roberta Paliotti; Arturo Esposito; Javier Dìez; Begoña López; Björn Dahlöf; M Gary Nicholls; Ronald D Smith; Leen Gilles; Fabio Magrini; Alberto Zanchetti Journal: Circulation Date: 2004-07-26 Impact factor: 29.690
Authors: Jasper W L Hartog; Adriaan A Voors; Stephan J L Bakker; Andries J Smit; Dirk J van Veldhuisen Journal: Eur J Heart Fail Date: 2007-12 Impact factor: 15.534
Authors: Salim Yusuf; Marc A Pfeffer; Karl Swedberg; Christopher B Granger; Peter Held; John J V McMurray; Eric L Michelson; Bertil Olofsson; Jan Ostergren Journal: Lancet Date: 2003-09-06 Impact factor: 79.321